To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil

PHASE3CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

November 27, 2023

Study Completion Date

May 24, 2024

Conditions
Essential Hypertension
Interventions
DRUG

Allisartan Isoproxil/Sustained-Release Indapamide

"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil/Sustained-Release Indapamide.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."

DRUG

Allisartan Isoproxil

"Double-blind period (Week 1\~Week 12): Allisartan Isoproxil.~Open-label period (Week 13\~Week 52): Allisartan Isoproxil/Sustained-Release Indapamide."

Trial Locations (40)

Unknown

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Xuancheng People's Hospital, Xuancheng

Aerospace Central Hospital, Beijing

China-Japan Friendship Hospital, Beijing

Chongqing University Affiliated Three Gorges Hospital, Chongqing

The First Affiliated Hospital of Fujian Medical University, Fuzhou

Gansu Provincial People's Hospital, Lanzhou

Shunde Hospital of Southern Medical University, Foshan

Guangdong Medical University Affiliated Hospital, Zhanjiang

Nanning First People's Hospital, Nanning

Hebei Provincial People's Hospital, Shijiazhuang

Shijiazhuang People's Hospital, Shijiazhuang

The Fourth Hospital of Hebei Medical University, Shijiazhuang

The Third Hospital of Hebei Medical University, Shijiazhuang

Daqing People's Hospital, Daqing

Kaifeng Traditional Chinese Medicine Hospital, Kaifeng

Chinese Medicine Dongfeng General Hospital, Shiyan

Wuhan First Hospital, Wuhan

Wuhan Fourth Hospital, Wuhan

Wuhan Sixth Hospital, Wuhan

Xiangya Second Hospital of Central South University, Changsha

Yueyang Central Hospital, Yueyang

Yueyang People's Hospital, Yueyang

Huai'an First People's Hospital, Huai'an

Suzhou Municipal Hospital, Suzhou

Xuzhou Central Hospital, Xuzhou

Ganzhou People's Hospital, Ganzhou

The First Affiliated Hospital of Gannan Medical College, Ganzhou

Pingxiang People's Hospital, Pingxiang

Tonghua Central Hospital, Tonghua

The Second Hospital of Shanxi Medical University, Taiyuan

Shanxi Provincial People's Hospital, Xi’an

West China Hospital of Sichuan University, Chengdu

Nanchong Central Hospital, Nanchong

Suining Central Hospital, Suining

Tianjin Medical University General Hospital, Tianjin

The Second Affiliated Hospital of Kunming Medical University, Kunming

Li Huili Hospital of Ningbo Medical Center, Ningbo

Quzhou People's Hospital, Quzhou

Wenzhou Medical University Affiliated First Hospital, Wenzhou

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY

NCT06500689 - To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil | Biotech Hunter | Biotech Hunter